Craig L Leonardi
Overview
Explore the profile of Craig L Leonardi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
3724
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gulliver W, See K, Zhu B, Konicek B, Harrison R, McLean R, et al.
J Psoriasis Psoriatic Arthritis
. 2024 Sep;
8(2):74-82.
PMID: 39296674
Background: Dermatologists would benefit from an easy to use psoriasis severity assessment tool in the clinic. Objective: To develop psoriasis assessment tools to predict PASI and Dermatology Life Quality Index...
2.
Pollard B, McCoy 4th W, Leonardi C, Martin A
JAAD Case Rep
. 2022 Sep;
27:128-130.
PMID: 36046802
No abstract available.
3.
Leonardi C, See K, Burge R, Sun Z, Zhang Y, Mallbris L, et al.
Adv Ther
. 2022 Mar;
39(5):2256-2269.
PMID: 35316500
Introduction: Number needed to treat (NNT) estimates are a practical metric to help identify the most effective therapies. Our objective is to compare 11 biologic drugs for moderate-to-severe psoriasis in...
4.
Papp K, Gerdes S, Leonardi C, Elmaraghy H, See K, McKean-Matthews M, et al.
J Drugs Dermatol
. 2021 Aug;
20(8):880-887.
PMID: 34397207
Background: Long-term efficacy, safety, and quality of life with ixekizumab (IXE) through 5 years in UNCOVER-1 and UNCOVER-2 patients with baseline scalp, nail, or palmoplantar psoriasis were assessed. Methods: Patients...
5.
Bissonnette R, Gottlieb A, Langley R, Leonardi C, Papp K, Pariser D, et al.
Drug Saf
. 2021 Jun;
44(6):699-709.
PMID: 34075572
Introduction: Psoriasis Longitudinal Assessment and Registry (PSOLAR) was designed in 2007 as the first disease-based registry for patients with psoriasis. Objective: The aim of this study was to discuss methodological...
6.
Blauvelt A, Leonardi C, Gaylis N, Jauch-Lembach J, Balfour A, Lemke L, et al.
BioDrugs
. 2021 Mar;
35(2):229-238.
PMID: 33651341
Background: SDZ-ADL (GP2017; Sandoz GmbH, Austria) is an EMA-/FDA-approved adalimumab biosimilar. The effect of SDZ-ADL on quality of life (QoL) and patient-reported outcomes (PROs) was assessed as part of two...
7.
Lebwohl M, Leonardi C, Mehta N, Gottlieb A, Mendelsohn A, Parno J, et al.
J Am Acad Dermatol
. 2020 Sep;
84(2):398-407.
PMID: 32961255
Background: Data for the effect of metabolic syndrome (MetS) on the efficacy and safety of biologic agents for psoriasis treatment are limited. Objective: To evaluate long-term tildrakizumab efficacy, drug survival,...
8.
Elmets C, Korman N, Prater E, Wong E, Rupani R, Kivelevitch D, et al.
J Am Acad Dermatol
. 2020 Aug;
84(2):432-470.
PMID: 32738429
Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the United States population. This guideline addresses important clinical questions that arise in psoriasis management and care...
9.
Blauvelt A, Leonardi C, Gooderham M, Papp K, Philipp S, Wu J, et al.
JAMA Dermatol
. 2020 Apr;
156(6):649-658.
PMID: 32267471
Importance: Risankizumab selectively inhibits interleukin 23, a cytokine that contributes to psoriatic inflammation. Objective: To evaluate the efficacy and safety of risankizumab vs placebo and continuous treatment vs withdrawal in...
10.
Menter A, Gelfand J, Connor C, Armstrong A, Cordoro K, Davis D, et al.
J Am Acad Dermatol
. 2020 Mar;
82(6):1445-1486.
PMID: 32119894
Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world's population. In this guideline, we focus the discussion on systemic, nonbiologic medications for...